Michael Graf

Michael Graf

Auto-generated profile, based on publicly available information

Michael Graf

Gene Center and Department for Biochemistry, University of Munich, 81377 Munich, Germany

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
TFTanja Florin
Tanja Florin
CMCristina Maracci
Cristina Maracci
MGMichael Graf
Michael Graf
PKPrajwal Karki
Prajwal Karki
DKDorota Klepacki
Dorota Klepacki
AMAlexander S Mankin
Alexander S Mankin
Antimicrobial peptide Api137 inhibits translation by trapping release factors 1 or 2 associated with ribosomes and arresting termination. Many antibiotics stop bacterial growth by inhibiting different steps of protein synthesis. However, no specific inhibitors of translation termination are known. Proline-rich antimicrobial peptides, a component of the antibacterial defense system of multicellular organisms, interfere with bacterial growth by inhibiting translation. Here we show that Api137, a derivative of the insect-produced antimicrobial peptide apidaecin, arrests terminating ribosomes using a unique mechanism of action. Api137 binds to the Escherichia coli ribosome and traps release factor (RF) RF1 or RF2 subsequent to the release of the nascent polypeptide chain. A high-resolution cryo-EM structure of the ribosome complexed with RF1 and Api137 reveals the molecular interactions that lead to RF trapping. Api137-mediated depletion of the cellular pool of free release factors causes the majority of ribosomes to stall at stop codons before polypeptide release, thereby resulting in a global shutdown of translation termination.

18 May 2015 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
ASA Carolin Seefeldt
A Carolin Seefeldt
FNFabian Nguyen
Fabian Nguyen
SAStéphanie Antunes
Stéphanie Antunes
NPNatacha Pérébaskine
Natacha Pérébaskine
MGMichael Graf
Michael Graf
CIC Axel Innis
C Axel Innis

24 May 2017 in Natural Product Reports
Verified
Journal Article
Closed access
PDF file
MGMichael Graf
Michael Graf
MMMario Mardirossian
Mario Mardirossian
FNFabian Nguyen
Fabian Nguyen
ASA. Carolin Seefeldt
A. Carolin Seefeldt
GGGilles Guichard
Gilles Guichard
DWDaniel Wilson
Daniel Wilson
Proline-rich antimicrobial peptides (PrAMPs) bind within the exit tunnel of the ribosome and inhibit translation elongation. Structures of ribosome-bound PrAMPs reveal the interactions with ribosomal components and could pave the way for the development of novel peptide-based antimicrobial agents.

1 November 2017 in Molecular Cell
Verified
Journal Article
Closed access
PHPaul Huter
Paul Huter
SAStefan Arenz
Stefan Arenz
LBLars V. Bock
Lars V. Bock
MGMichael Graf
Michael Graf
JFJan Ole Frister
Jan Ole Frister
DWDaniel Wilson
Daniel Wilson

6 July 2016 in Nature Communications
Verified
Journal Article
Open access
SAStefan Arenz
Stefan Arenz
LBLars V. Bock
Lars V. Bock
MGMichael Graf
Michael Graf
CIC. Axel Innis
C. Axel Innis
RBRoland Beckmann
Roland Beckmann
DWDaniel Wilson
Daniel Wilson
Nascent polypeptides can induce ribosome stalling, regulating downstream genes. Stalling of ErmBL peptide translation in the presence of the macrolide antibiotic erythromycin leads to resistance in Streptococcus sanguis. To reveal this stalling mechanism we obtained 3.6-Å-resolution cryo-EM structures of ErmBL-stalled ribosomes with erythromycin. The nascent peptide adopts an unusual conformation with the C-terminal Asp10 side chain in a previously unseen rotated position. Together with molecular dynamics simulations, the structures indicate that peptide-bond formation is inhibited by displacement of the peptidyl-tRNA A76 ribose from its canonical position, and by non-productive interactions of the A-tRNA Lys11 side chain with the A-site crevice. These two effects combine to perturb peptide-bond formation by increasing the distance between the attacking Lys11 amine and the Asp10 carbonyl carbon. The interplay between drug, peptide and ribosome uncovered here also provides insight into the fundamental mechanism of peptide-bond formation.

20 January 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
ASA. Carolin Seefeldt
A. Carolin Seefeldt
MGMichael Graf
Michael Graf
NPNatacha Pérébaskine
Natacha Pérébaskine
FNFabian Nguyen
Fabian Nguyen
SAStefan Arenz
Stefan Arenz
CIC. Axel Innis
C. Axel Innis
Proline-rich antimicrobial peptides (PrAMPs) produced as part of the innate immune response of animals, insects and plants represent a vast, untapped resource for the treatment of multidrug-resistant bacterial infections. PrAMPs such as oncocin or bactenecin-7 (Bac7) interact with the bacterial ribosome to inhibit translation, but their supposed specificity as inhibitors of bacterial rather than mammalian protein synthesis remains unclear, despite being key to developing drugs with low toxicity. Here, we present crystal structures of the Thermus thermophilus 70S ribosome in complex with the first 16 residues of mammalian Bac7, as well as the insect-derived PrAMPs metalnikowin I and pyrrhocoricin. The structures reveal that the mammalian Bac7 interacts with a similar region of the ribosome as insect-derived PrAMPs. Consistently, Bac7 and the oncocin derivative Onc112 compete effectively with antibiotics, such as erythromycin, which target the ribosomal exit tunnel. Moreover, we demonstrate that Bac7 allows initiation complex formation but prevents entry into the elongation phase of translation, and show that it inhibits translation on both mammalian and bacterial ribosomes, explaining why this peptide needs to be stored as an inactive pro-peptide. These findings highlight the need to consider the specificity of PrAMP derivatives for the bacterial ribosome in future drug development efforts.